Stockreport

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net p [Read more]